![conference banner](/images/conference-banner.jpeg)
Abstract
Kynurenines are a wide range of catabolites which derive from tryptophan through the “Kynurenine Pathway” (KP). In addition to its peripheral role, increasing evidence shows a role of the KP in the central nervous system (CNS), mediating both physiological and pathological functions. Indeed, an imbalance in this route has been associated with several neurodegenerative disorders such as Alzheimer´s and Huntington´s diseases. Altered KP catabolism has also been described during both acute and chronic phases of stroke; however the contribution of the KP to the pathophysiology of acute ischemic damage and of post-stroke disorders during the chronic phase including depression and vascular dementia, and the exact mechanisms implicated in the regulation of the KP after stroke are not well established yet. A better understanding of the regulation and activity of the KP after stroke could provide new pharmacological tools in both acute and chronic phases of stroke. In this review, we will make an overview of CNS modulation by the KP. We will detail the KP contribution in the ischemic damage, how the unbalance of the KP might trigger an alteration of the cognitive function after stroke as well as potential targets for the development of new drugs.
Keywords: Tryptophan, kynurenine, ischemia, stroke, neurodegeneration, depression, cognitive impairment, dementia.
Current Pharmaceutical Design
Title:The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia
Volume: 22 Issue: 8
Author(s): María Isabel Cuartero, Juan de la Parra, Alicia García-Culebras, Iván Ballesteros, Ignacio Lizasoain and María Ángeles Moro
Affiliation:
Keywords: Tryptophan, kynurenine, ischemia, stroke, neurodegeneration, depression, cognitive impairment, dementia.
Abstract: Kynurenines are a wide range of catabolites which derive from tryptophan through the “Kynurenine Pathway” (KP). In addition to its peripheral role, increasing evidence shows a role of the KP in the central nervous system (CNS), mediating both physiological and pathological functions. Indeed, an imbalance in this route has been associated with several neurodegenerative disorders such as Alzheimer´s and Huntington´s diseases. Altered KP catabolism has also been described during both acute and chronic phases of stroke; however the contribution of the KP to the pathophysiology of acute ischemic damage and of post-stroke disorders during the chronic phase including depression and vascular dementia, and the exact mechanisms implicated in the regulation of the KP after stroke are not well established yet. A better understanding of the regulation and activity of the KP after stroke could provide new pharmacological tools in both acute and chronic phases of stroke. In this review, we will make an overview of CNS modulation by the KP. We will detail the KP contribution in the ischemic damage, how the unbalance of the KP might trigger an alteration of the cognitive function after stroke as well as potential targets for the development of new drugs.
Export Options
About this article
Cite this article as:
Cuartero Isabel María, la Parra de Juan, García-Culebras Alicia, Ballesteros Iván, Lizasoain Ignacio and Moro Ángeles María, The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia, Current Pharmaceutical Design 2016; 22 (8) . https://dx.doi.org/10.2174/1381612822666151214125950
DOI https://dx.doi.org/10.2174/1381612822666151214125950 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Link between Metabolic Syndrome and Insulin Resistance
Current Vascular Pharmacology Management of Hypertension in Relation to Acute Coronary Syndromes and Revascularisation
Current Pharmaceutical Design Oral Health in Alzheimers Disease: A Review
Current Alzheimer Research Primary Hypertriglyceridemia: A Look Back on the Clinical Classification and Genetics of the Disease
Current Diabetes Reviews Recent Patents Relating to siRNAs and Therapeutic Strategies for Genetic Diseases
Recent Patents on DNA & Gene Sequences Non-B DNA Structures as Candidate Drug Targets Against Structural Chromosomal Instability
Current Pharmacogenomics and Personalized Medicine Hydroxychloroquine (HCQ) Treatment for Hospitalized Patients with COVID- 19
Infectious Disorders - Drug Targets Biomarkers Associated with Vulnerable Atheromatous Plaque
Current Medicinal Chemistry Role of AGEs-RAGE System in Cardiovascular Disease
Current Pharmaceutical Design Pearls from the First Gulf Cardiac Amyloidosis Summit 2021
New Emirates Medical Journal The Early Involvement of the Innate Immunity in the Pathogenesis of Lateonset Alzheimers Disease: Neuropathological, Epidemiological and Genetic Evidence
Current Alzheimer Research Hydrogen Peroxide Produced by Mitochondrial Monoamine Oxidase Catalysis: Biological Implications
Current Pharmaceutical Design Homocysteine, Vitamin B12 and Folate Level: Possible Risk Factors in the Progression of Chronic Heart and Kidney Disorders
Current Cardiology Reviews Clinical Trials: How to Assess Confounding and Why So
Current Clinical Pharmacology Copper Chelators: Chemical Properties and Bio-medical Applications
Current Medicinal Chemistry Adiponectin: A Key Player in Obesity Related Disorders
Current Pharmaceutical Design Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD
Current Pharmaceutical Design The Gut and Intestinal Bacteria in Chronic Heart Failure
Current Drug Metabolism Immunomodulatory Gene Therapy in Lysosomal Storage Disorders
Current Gene Therapy Re-Wiring the Circuit: Mitochondria as a Pharmacological Target in Liver Disease
Current Medicinal Chemistry